{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:26:44Z","timestamp":1787243204357,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002129"],"award-info":[{"award-number":["82002129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2024-4-1142"],"award-info":[{"award-number":["2024-4-1142"]}]},{"name":"Beijing Hospitals Authority Innovation Studio of Young Staff Funding","award":["202328"],"award-info":[{"award-number":["202328"]}]},{"name":"2022 Scientific Research Project of Chronic Diseases Control and Health Education","award":["BJMB0012022028010"],"award-info":[{"award-number":["BJMB0012022028010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPDs) are a group of disorders involving lymphoid tissues or lymphocytes. The epidemiology and economic burden of hospitalized children with EBV-LPDs in China have not been well studied. This study aimed to reveal the epidemic characteristics and disease burden of EBV-LPDs among the Chinese hospitalized children, providing strategies for the prevention and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was based on the FUTang Updating medical REcords (FUTURE) database of China and collected the medical records from 27 tertiary children\u2019s hospitals between January 2016 and December 2021 in China, counting five types of EBV-LPDs, namely EBV-positive T-cell lymphoproliferative disease, NK\/T cell lymphoma, extranodal NK\/T-cell lymphoma (nasal type), systemic EBV-positive T-cell lymphoproliferative disease of childhood and posttransplant lymphoproliferative disorders. We conducted a retrospective syhthesis and analysis of the epidemiological characteristics, expenses, length of stay (LOS), as well as complications among hospitalized children diagnosed with five types of EBV-LPDs and compared parameters using appropriate statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study described 153 children aged 0\u201318\u00a0years hospitalized with EBV-LPDs from 2016 to 2021 in the FUTURE database. The male-to-female ratio was 1.10:1, and more than half of the age distribution was in the 6\u201312 y group. Among EBV-LPDs cases, EBV\n                      <jats:sup>+<\/jats:sup>\n                      T-LPD accounted for the largest proportion (65.36%). Complications were presented in 93 children with EBV-LPDs, mainly hemophagocytic lymphohistiocytosis (HLH). The median LOS of NKTL was 26.5\u00a0days [interquartile range (IQR)\u2009=\u20093\u201342], which was the longest among EBV-LPDs. The median hospitalization cost of PTLD was 10 785.74 United States dollars (IQR\u2009=\u20097 329.38\u201316 531.18), which was the heaviest among EBV-LPDs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Compared with the total number of hospitalized children in China during the same period and in the same age group, the proportion of EBV-LPD is very low. EBV-LPD can develop in all age groups, but it is more common in school-age children. Among 5 EBV-LPDs, the disease with the highest proportion is EBV\n                      <jats:sup>+<\/jats:sup>\n                      T-LPD. The overall disease burden of EBV-LPD was heavy, especially the economic burden. HLH was one of the most common complications, which could directly affect the burden of patients because of prolonged hospitalization. These data are taken from a very large database, illustrating the epidemiological and economic burden of EBV-LPDs hospitalized children in China, which enriched the existing epidemiological and disease burden content of EBV-LPDs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-024-01685-y","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:02:49Z","timestamp":1719885769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study\u00a0in China"],"prefix":"10.1186","volume":"50","author":[{"given":"Dilara","family":"Dilmurat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-8538","authenticated-orcid":false,"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengde","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"7","key":"1685_CR1","first-page":"983","volume":"139","author":"K Toner","year":"2022","unstructured":"Toner K, Bollard CM. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood, J American Soc Hematol. 2022;139(7):983\u201394.","journal-title":"Blood, J American Soc Hematol"},{"issue":"20","key":"1685_CR2","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"key":"1685_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.838817","volume":"12","author":"K Lv","year":"2022","unstructured":"Lv K, Yin T, Yu M, Chen Z, Zhou Y, Li F. Treatment Advances in EBV Related Lymphoproliferative Diseases. Front Oncol. 2022;12: 838817.","journal-title":"Front Oncol"},{"key":"1685_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2019.00109","volume":"9","author":"JL Crombie","year":"2019","unstructured":"Crombie JL, LaCasce AS. Epstein Barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders. Front Oncol. 2019;9:109.","journal-title":"Front Oncol"},{"key":"1685_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fped.2019.00071","volume":"7","author":"WY Kim","year":"2019","unstructured":"Kim WY, Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019;7:71.","journal-title":"Front Pediatr"},{"issue":"4","key":"1685_CR6","doi-asserted-by":"publisher","first-page":"e2328","DOI":"10.1002\/rmv.2328","volume":"32","author":"A Shafiee","year":"2022","unstructured":"Shafiee A, Shamsi S, Gargari OK, Beiky M, Allahkarami MM, Miyanaji AB, et al. EBV associated T- and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights. Rev Med Virol. 2022;32(4):e2328.","journal-title":"Rev Med Virol"},{"key":"1685_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-95","volume":"8","author":"M Lima","year":"2013","unstructured":"Lima M. Aggressive mature natural killer cell neoplasms: from epidemiology todiagnosis. Orphanet J Rare Dis. 2013;8:1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1685_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","volume":"11","author":"A Phan","year":"2016","unstructured":"Phan A, Veldman R, Lechowicz MJ. T-cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep. 2016;11(6):492\u2013503.","journal-title":"Curr Hematol Malig Rep"},{"issue":"10357","key":"1685_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S0140-6736(22)01541-0","volume":"400","author":"X Ni","year":"2022","unstructured":"Ni X, Li Z, Li X, Zhang X, Bai G, Liu Y, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study. The Lancet. 2022;400(10357):1020\u201332.","journal-title":"The Lancet"},{"key":"1685_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867918","volume":"13","author":"GM Escalante","year":"2022","unstructured":"Escalante GM, Mutsvunguma LZ, Muniraju M, Rodriguez E, Ogembo JG. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective. Front Immunol. 2022;13: 867918.","journal-title":"Front Immunol"},{"issue":"1","key":"1685_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00428-022-03414-4","volume":"482","author":"L Quintanilla-Martinez","year":"2023","unstructured":"Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482(1):227\u201344.","journal-title":"Virchows Arch"},{"key":"1685_CR12","doi-asserted-by":"crossref","unstructured":"Health Commission Of The People's Republic Of China. National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China. Chin J Cancer Res. 2022;34(5):425\u201346.","DOI":"10.21147\/j.issn.1000-9604.2022.05.01"},{"issue":"9","key":"1685_CR13","first-page":"10","volume":"43","author":"Chinese Society of Hematology CMA","year":"2022","unstructured":"Chinese Society of Hematology CMA, China Hematology Association, Chinese Medical Doctor Association. Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022). Zhonghua Xue Ye Xue Za Zhi. 2022;43(9):10.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1685_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.humpath.2018.05.020","volume":"79","author":"SA Rezk","year":"2018","unstructured":"Rezk SA, Zhao X, Weiss LM. Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update. Hum Pathol. 2018;79:18\u201341.","journal-title":"Hum Pathol"},{"issue":"20","key":"1685_CR15","first-page":"2375","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, The Journal of the American Society of Hematology. 2016;127(20):2375\u201390.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"4","key":"1685_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2328","volume":"32","author":"A Shafiee","year":"2022","unstructured":"Shafiee A, Shamsi S, Kohandel Gargari O, Beiky M, Allahkarami MM, Miyanaji AB, et al. EBV associated T-and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights. Rev Med Virol. 2022;32(4): e2328.","journal-title":"Rev Med Virol"},{"issue":"8","key":"1685_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/PAS.0000000000001495","volume":"44","author":"Z Chen","year":"2020","unstructured":"Chen Z, Wang M, Guan P, Zhao S, Zhang W, Gao L, et al. Comparison of Systemic EBV-positive T-Cell and NK-Cell Lymphoproliferative Diseases of Childhood Based on Classification Evolution: New Classification, Old Problems. Am J Surg Pathol. 2020;44(8):1061\u201372.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1685_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ijc.22313","volume":"120","author":"JX Xu","year":"2007","unstructured":"Xu JX, Hoshida Y, Yang WI, Inohara H, Kubo T, Kim GE, et al. Life-style and environmental factors in the development of nasal NK\/T-cell lymphoma: A case\u2013control study in East Asia. Int J Cancer. 2007;120(2):406\u201310.","journal-title":"Int J Cancer"},{"issue":"3","key":"1685_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3816\/CLM.2003.n.025","volume":"4","author":"BCH Chiu","year":"2003","unstructured":"Chiu BCH, Weisenburger DD. An update of the epidemiology of non-Hodgkin\u2019s lymphoma. Clin Lymphoma. 2003;4(3):161\u20138.","journal-title":"Clin Lymphoma"},{"issue":"12","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00277-016-2805-9","volume":"95","author":"J Jia","year":"2016","unstructured":"Jia J, Song Y, Lin N, Liu W, Ping L, Zheng W, et al. Clinical features and survival of extranodal natural killer\/T cell lymphoma with and without hemophagocytic syndrome. Ann Hematol. 2016;95(12):2023\u201331.","journal-title":"Ann Hematol"},{"issue":"1","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","volume":"2015","author":"CE Allen","year":"2015","unstructured":"Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015;2015(1):177\u201382.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"1685_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 2018;13:27\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","volume":"11","author":"J Nourse","year":"2011","unstructured":"Nourse J, Jones K, Gandhi M. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant. 2011;11(5):888\u201395.","journal-title":"Am J Transplant"},{"key":"1685_CR24","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1182\/blood-2023-187969","volume":"142","author":"M Orland","year":"2023","unstructured":"Orland M, Sheu M, Patel M, Adcock B, Ardila V, Shrivastava G, et al. Infectious Complications and Mortality in Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation: Experiences of 10 Years in a Single Center. Blood. 2023;142:4404.","journal-title":"Blood"},{"issue":"05","key":"1685_CR25","first-page":"24","volume":"24","author":"Y Lv","year":"2023","unstructured":"Lv Y, Zeng Y, Tian M, Song F, Zhang X, Liu S. Research on Coding of Chronic Active Epstein-Barr Virus Infection. Chinese Medical Record. 2023;24(05):24\u20136.","journal-title":"Chinese Medical Record"},{"key":"1685_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fped.2018.00417","volume":"6","author":"H Kimura","year":"2018","unstructured":"Kimura H, Fujiwara S. Overview of EBV-Associated T\/NK-Cell Lymphoproliferative Diseases. Front Pediatr. 2018;6:417.","journal-title":"Front Pediatr"},{"issue":"2","key":"1685_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4132\/KoreanJPathol.2013.47.2.137","volume":"47","author":"M Hong","year":"2013","unstructured":"Hong M, Ko YH, Yoo KH, Koo HH, Kim SJ, Kim WS, et al. EBV-positive T\/NK-cell lymphoproliferative disease of childhood. Korean Journal of Pathology. 2013;47(2):137.","journal-title":"Korean Journal of Pathology"},{"issue":"2","key":"1685_CR28","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/HS9.0000000000000523","volume":"5","author":"JA van Doesum","year":"2021","unstructured":"van Doesum JA, Niezink AG, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal natural killer\/T-cell lymphoma, nasal type: diagnosis and treatment. Hemasphere. 2021;5(2):e523.","journal-title":"Hemasphere"},{"issue":"9","key":"1685_CR29","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H. Fu B-b, Gale RP, Liang Y. NK-\/T-cell lymphomas. Leukemia. 2021;35(9):2460\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"1685_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0452-9","volume":"10","author":"E Tse","year":"2017","unstructured":"Tse E, Kwong Y-L. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017;10(1):1\u201313.","journal-title":"J Hematol Oncol"},{"issue":"S1","key":"1685_CR31","first-page":"EP1238","volume":"4","author":"J van Doesum","year":"2020","unstructured":"van Doesum J, Nijland M, Brink M, Huls G, van Meerten T. A West-European cohort of patients with NK\/T-cell lymphoma, a population-based analysis. HemaSphere. 2020;4(S1):EP1238.","journal-title":"HemaSphere."},{"key":"1685_CR32","doi-asserted-by":"crossref","unstructured":"Karkera AC, Parsons BM, Borgert A, Go RS. NK\/T cell lymphoma in the US: A population based study using the National Cancer Database from 1998\u20132012.\u00a0Am Soc Clin Oncol.\u00a02016;34(15):e19038.","DOI":"10.1200\/JCO.2016.34.15_suppl.e19038"},{"issue":"25","key":"1685_CR33","first-page":"4997","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse E, Kwong Y-L. How I treat NK\/T-cell lymphomas. Blood, The Journal of the American Society of Hematology. 2013;121(25):4997\u20135005.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"1","key":"1685_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2141.2010.08461.x","volume":"152","author":"YL Kwong","year":"2011","unstructured":"Kwong YL, Khong PL. Central palatal perforation in nasal natural killer cell lymphoma. Br J Haematol. 2011;152(1):2.","journal-title":"Br J Haematol."},{"issue":"7","key":"1685_CR35","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Araujo IB, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"key":"1685_CR36","unstructured":"Quintanilla-Martinez L, Ko Y, Kimura H, Jaffe E. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. WHO classification of tumours of haematopoietic and lymphoid tissues. 2017:355\u201362."},{"issue":"1","key":"1685_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.semdp.2019.12.004","volume":"37","author":"IA Montes-Mojarro","year":"2020","unstructured":"Montes-Mojarro IA, Kim WY, Fend F, Quintanilla-Martinez L. Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis. Semin Diagn Pathol. 2020;37(1):32\u201346.","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"1685_CR38","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1038\/emm.2014.105","volume":"47","author":"Q Cai","year":"2015","unstructured":"Cai Q, Chen K, Young KH. Epstein-Barr virus-positive T\/NK-cell lymphoproliferative disorders. Experimental & Molecular Medicine. 2015;47(1):e133.","journal-title":"Experimental & Molecular Medicine."},{"key":"1685_CR39","doi-asserted-by":"crossref","unstructured":"Burns DM, Chaganti S. Epstein-Barr virus-associated lymphoproliferative disorders in immunosuppressed patients.\u00a0Ann Lymphoma. 2021;5(24):1\u201318.","DOI":"10.21037\/aol-20-42"},{"issue":"6","key":"1685_CR40","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","volume":"21","author":"RH Rouce","year":"2014","unstructured":"Rouce RH, Louis CU, Heslop HE. EBV lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21(6):476.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"1685_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/10428194.2018.1474462","volume":"60","author":"S Romero","year":"2019","unstructured":"Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma. 2019;60(1):142\u201350.","journal-title":"Leuk Lymphoma"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-024-01685-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:05:28Z","timestamp":1719885928000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-024-01685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s13052-024-01685-y","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Children's Hospital, Capital Medical University (Approval No.: [2023]-E-053-R). Because this study involved only a retrospective aggregated data analysis of medical records, patients informed consent was not required. To protect patients\u2019 privacy, our data are fully de-identified and anonymized. This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. The authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}